Analyst Kostas Biliouris of BMO Capital maintained a Buy rating on Prime Medicine, Inc. (PRME – Research Report), retaining the price target of $19.00.
Kostas Biliouris has given his Buy rating due to a combination of factors that highlight Prime Medicine, Inc.’s promising future in the gene editing landscape. The company is advancing an Alpha-1 Antitrypsin Deficiency (AATD) program that utilizes prime editing technology, which is expected to deliver a best-in-class profile. This program targets specific mutations in the SERPINA1 gene, potentially offering a more efficient editing process compared to competitors. The anticipated clinical entry in mid-2026 and subsequent data readout in 2027 are key milestones that could significantly enhance Prime Medicine’s market position.
Additionally, Prime Medicine’s preclinical data suggests high efficacy and safety, with minimal liver function test elevations, which is crucial for investor confidence. The company’s strategic approach, including potential business development deals, is expected to mitigate financial risks and support growth. The differentiation of prime editing technology, with its high specificity and versatility, positions Prime Medicine favorably against other gene editing approaches, potentially leading to broader applicability and market capture. These factors collectively underpin Biliouris’s optimistic outlook and Buy rating for Prime Medicine’s stock.
In another report released today, JMP Securities also maintained a Buy rating on the stock with a $10.00 price target.
PRME’s price has also changed dramatically for the past six months – from $3.980 to $1.760, which is a -55.78% drop .
Questions or Comments about the article? Write to editor@tipranks.com